The performance of the two-stage analysis of two-treatment, two-period crossover trials.
about
Oral probiotics for infantile colicPimozide for tics in Tourette's syndromeNonabsorbable disaccharides for hepatic encephalopathyContemporary meta-analysis of short-term probiotic consumption on gastrointestinal transitOn the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publicationsMeasuring inconsistency in meta-analysesEstimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs.Testing equality and interval estimation of the generalized odds ratio in ordinal data under a three-period crossover design.Estimation of the treatment effect under an incomplete block crossover design in binary data - A conditional likelihood approach.Milk protein-based formulas containing different oils affect fatty acids balance in term infants: A randomized blinded crossover clinical trial.Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]).Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil.Understanding controlled trials. Crossover trialsAccounting for centre-effects in multicentre trials with a binary outcome - when, why, and how?The method quality of cross-over studies involved in Cochrane Systematic ReviewsDesign, Analysis, and Reporting of Crossover Trials for Inclusion in a Meta-Analysis.A re-randomisation design for clinical trials.A comparison of methods to adjust for continuous covariates in the analysis of randomised trialsTesting for carryover effects after cessation of treatments: a design approach.Coping with persistent pain, effectiveness research into self-management (COPERS): statistical analysis plan for a randomised controlled trial.Improper analysis of trials randomised using stratified blocks or minimisation.Linear combinations come alive in crossover designs.Crossover design and its application in late-phase diabetes studies.Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over.Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes.Alternative designs for clinical trials in rare diseases.Crossover designs in lower extremity wounds.Choosing appropriate analysis methods for cluster randomised cross-over trials with a binary outcome.Clinical trials in chronic diseases.An objective Bayesian analysis of a crossover design via model selection and model averaging.Review of nonparametric methods for the analysis of crossover studies.Carryover negligibility and relevance in bioequivalence studies.The AB/BA crossover: past, present and future?Choosing sensitivity analyses for randomised trials: principles.Should we cross off the crossover?Carryover bias in clinical investigations.Problems with the two stage analysis of crossover trials.Crossover trials with a cumulative response.An efficient analysis of covariance model for crossover thorough QT studies with period-specific pre-dose baselines.Applications of extensions of bivariate rank sum statistics to the crossover design to compare two treatments through four sequence groups.
P2860
Q24199006-6644085E-FD3C-4C64-8CDE-792EFAF695B8Q24241313-DAB7A86C-A255-4566-890F-8BD39ADF5092Q24247141-3389F551-76A9-41D6-BFC4-AAD1D4543EE0Q24658598-33BA70D3-D49F-4847-98C0-95893BE77401Q26998021-4CB70A58-3E74-4DB8-A4D5-FAEFBAC31022Q27860655-141F911C-EF7A-4AB9-A61D-2D1DE117A44FQ30651693-09D8125E-817D-4EA9-A67E-A8F51B5A15C5Q30891267-2FB9465A-6B4A-4E39-A548-9D42B80D6D88Q30981049-E8852EA9-067D-4E5B-BA1B-B0F9914B7E50Q33564526-38117056-3756-472B-92C2-4D7B96415E8CQ33633414-3E810402-DED3-4173-9C32-07913D8B0E07Q33776631-D150E000-C0D5-4162-BC91-987791A2D265Q33790432-9E5D7AEF-76A5-41B9-9DE3-50C774343587Q35089861-2A0E370F-B748-47B7-9B09-0DFFE89CB94FQ35600294-D22D33EE-7F25-4AA0-9B0F-B4B96DB0909CQ35748752-039AE0CF-CA06-4074-B05A-965A6C664598Q35834036-8215A0D4-DFD5-4030-8E89-D005DAC665C2Q35986625-A746B760-5F60-46EC-A45E-78BC4C0A583CQ36093297-C17FE776-1BF1-4C63-A987-E9A9BE19D31BQ37595129-E1136254-68D0-4422-BE8E-AB0887FFA336Q37964613-5E0697AB-8042-48FE-AA20-25B120D1080AQ38661528-CCD904C8-4CFB-48B2-9206-CD3C41CBC78CQ38813734-BC7F920F-7041-46FE-8BAB-0826C0847DFEQ38958267-E1FC2546-A4A8-4CC2-A8D8-E7D0A1270327Q38958275-FECB32E2-C82A-4615-A42B-B3DA211E35D7Q39013156-C0798942-6C5C-40C3-894F-0C4B6524FA08Q39217104-A3820746-19E2-4757-8E9C-E316C04C7608Q39268655-D3D66C41-17DE-41A0-97D2-27D8AB3A2182Q39474432-138FD0EF-017D-47BE-85CB-2FEDA5AB2C7AQ39641631-ADD29C65-F099-48F8-BEAF-250BA6AECEAFQ40612177-EB3D0AC1-2D13-46B4-A6A1-989EE129A79DQ40736175-281E8548-23B5-4F07-A1C2-84CDE2687171Q41010101-D2758B50-2D09-4304-853E-908F1635B319Q41894864-FCD4F6F5-1877-4619-A836-3B649E40BF5FQ42248073-03F7F61C-9A8B-405D-8FFA-B64458526533Q42608664-BD31A22B-AB27-45AB-98A9-0AA95FE662C9Q43205015-934E9331-52DC-408E-8F64-07AE26F72B75Q43862928-0930A113-7B79-47C3-9388-8BFF8003F280Q46839858-D7142D43-4FBF-4276-A40E-3D211E88BA22Q48301340-D86DEAEF-9F80-41FD-B495-54FE3B567887
P2860
The performance of the two-stage analysis of two-treatment, two-period crossover trials.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
The performance of the two-stage analysis of two-treatment, two-period crossover trials.
@en
type
label
The performance of the two-stage analysis of two-treatment, two-period crossover trials.
@en
prefLabel
The performance of the two-stage analysis of two-treatment, two-period crossover trials.
@en
P356
P1476
The performance of the two-stage analysis of two-treatment, two-period crossover trials.
@en
P2093
Freeman PR
P304
P356
10.1002/SIM.4780081202
P407
P577
1989-12-01T00:00:00Z